Clinical trial
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who…
NCT00112918 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00112918 |
|---|---|
| Title | Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer |
| Official title | A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon… |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin |
| Enrollment | 3,451 |
| Start date | Dec 1, 2004 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2012 |
| First posted | Jun 3, 2005 |
| Last update posted | Aug 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: